VolitionRx Sells First NuQ® Research Use Only Kits to Active Motif
First revenues from VolitionRx Nucleosomics technology
NAMUR, Belgium, June 23, 2014 /PRNewswire/ — VolitionRx Limited (OTCQB: VNRX), a life sciences company, today announces its first wholesale order of NuQ® Research Use Only kits to Active Motif. Each kit allows epigenetics researchers to identify and analyze a different nucleosome structure. Active Motif will distribute the kits in its key markets of Europe, the United States and Japan.
These assays allow researchers — in areas as diverse as stem cells, apoptosis and epigenetic regulation — to study nucleosome based epigenetic features in animal or human cell culture samples. The four different types of kits which will be available through Active Motif are:
-- NuQ® Total Nucleosome Cell Culture ELISA (measures total nucleosomes in a cell culture sample) -- NuQ® H4K16(Ac) Cell Culture ELISA (measures nucleosome associated acetylated lysine 16 on histone H4 in a cell culture sample) -- NuQ® H4Pan(Ac) Cell Culture ELISA (measures nucleosome associated total acetylation on nucleosome associated H4 in a cell culture sample) -- NuQ® H2AZ Cell Culture ELISA (measures nucleosome associated histone variant H2AZ in a cell culture sample)
Cameron Reynolds, CEO of VolitionRx, commented, “Active Motif is a globally respected supplier of tools for use in the field of epigenetics research, so we are delighted to be partnering with them. Our kits have great potential in supporting cell culture research and we are excited to see them being made available through Active Motif’s sales and distribution network and to their extensive customer base. It’s fantastic for us to see our first revenues from Nucleosomics.”
“VolitionRx’s NuQ® ELISA research kits are an excellent complement to our existing range of epigenetics research products,” Gary Shiels PhD, Director of Global Marketing at Active Motif added. “We are always looking for innovative tests that can enable our researchers to track unique epigenetic characteristics and inspire them to experiment with new techniques.”
These kits are for research use only and are not approved for in vitro medical use. VolitionRx’s NuQ® epigenetics Research Use kits are also available via www.nucleosomics.com for a sales price of EUR495-EUR795, depending on the kit target.
VolitionRx is a life sciences company focused on developing blood-based diagnostic tests for different types of cancer. The tests are based on the science of Nucleosomics which is the practice of identifying and measuring nucleosomes in the bloodstream – an indication that cancer is present.
VolitionRx’s goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. VolitionRx’s research and development activities are currently centred in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the US and ultimately, worldwide.
About Active Motif
Active Motif, Inc. is dedicated to developing, manufacturing and delivering epigenetics-based research tools to analyze nuclear function. Its customers include life scientists from academic and government institutions; biotechnology and pharmaceutical companies; hospitals and reference laboratories. Active Motif operates globally through its corporate headquarters in Carlsbad, California regional headquarters in Belgium and Japan and a worldwide network of sales and support offices. Active Motif applies a multi-disciplinary approach to create new and modify existing technologies to meet the current and future needs of life science researchers.
Charlotte Reynolds, VolitionRx
Telephone: +44 (0) 795 217 7498
Eleanor Stuart, Racepoint Global
Telephone: +44 (0) 208 811 2124
Scott Powell, VolitionRx
Telephone: +1 917 721 9480
Active Motif Contact:
Gary Shiels, Active Motif
Telephone: 760 431 1263
Safe Harbor Statement
Statements in this press release may be “forward-looking statements”. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “optimizing,” “potential,” “goal,” and similar expressions, as they relate to the Company, its business or management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the Company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in the Company’s filings with the Securities and Exchange Commission.
SOURCE VolitionRX Ltd